LBP-1 is a drug originally developed by Organon for the treatment of neuropathic pain and subsequently further developed by Merck after they acquired Organon’s patents following their merger with Schering-Plough. It acts as a potent and selective cannabinoid receptor agonist with high potency at both the CB1 and CB2 receptors but low penetration of the blood–brain barrier.
This page contains content from the copyrighted Wikipedia article "LBP-1 (drug)"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
